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We have recently shown that selenium compounds can induce a senescence 
response in a manner depending on ataxia-telangiectasia mutated (ATM), DNA-
dependent protein kinase (DNA-PK), p53 and reactive oxygen species (ROS). To test the 
hypothesis that the selenium-induced senescence response involves epigenetic changes in 
senescence-associated heterochromatin foci (SAHF), we determined the expression of 
histone H3 Lysine 9 trimethylation (H3K9me3), a marker of SAHF, in human primary 
MRC-5 cells treated with methylseleninic acid (MSeA, 2 µM) for 2 days, followed by a 
7-day recovery, in the presence or absence of KU55933 (10 µM), an ATM kinase 
inhibitor, and NU7026 (10 µM), a DNA-PK kinase inhibitor. Our results showed that 
MSeA treatment induced the formation of SAHF and H3K9me3 foci. Pre-treatment of 
the cells with KU55955 or NU7026 resulted in numerous and smaller foci, and they did 
not co-localize with the MSeA-induced SAHF. These results suggest that the MSeA-
induced senescence response involves epigenetic changes of H3K9me3 in a manner 






















Thesis submitted to the Faculty of the Graduate School of the  
University of Maryland, College Park in partial fulfillment  
of the requirements for the degree of  















Professor Wen-Hsing Cheng, Chair   
Professor Robert Jackson 
Professor Seong-Ho Lee
 
	   ii	  
Table of Contents 
Chapter 1: Selenium, epigenetic regulation and DNA damage response .................... 1 
Introduction ....................................................................................................................... 1 
Selenium: Historical perspective and nutrition ............................................................. 1 
Selenoproteins ................................................................................................................... 3 
The GPX Family ............................................................................................................... 4 
Thioredoxin Reductase Family ........................................................................................ 7 
Selenoprotein P .................................................................................................................. 9 
Selenium and Epigenetics ................................................................................................. 9 
DNA Methylation ............................................................................................................ 10 
Selenium and DNMT ...................................................................................................... 11 
Histone Modifications ..................................................................................................... 12 
Stress-induced senescence .............................................................................................. 12 
Chapter 2: ........................................................................................................................ 18 
Materials and Methods ................................................................................................... 18 
Cell culture ...................................................................................................................... 18 
Immunofluorescence Microscopy .................................................................................. 18 
Quantification of SAHF positive cells ........................................................................... 20 
Statistics ............................................................................................................................ 20 
Chapter 3: Results - MSeA induces SAHF in a manner depending on the kinase 
activity of ATM and DNA-PK ....................................................................................... 21 
MSeA induces SAHF ...................................................................................................... 21 
Selenium-induced senescence involves ATM and DNA-PK........................................ 22 
Chapter 4: Discussion and Conclusion ......................................................................... 28 
Discussion ........................................................................................................................ 28 
Conclusion ....................................................................................................................... 30 






Chapter 1: Selenium, epigenetic regulation and DNA damage response 
Introduction 
 
Recent interest in the epigenetic changes modulated by selenium has grown due to the 
role of this essential nutrient in chemoprevention, DNA damage and epigenetic 
reglation1,2. The role of selenium and the selenoproteins that are developed from the 
mineral are widely studied and it is known that they reduce oxidative stress in 
mammalian cells3,4. Although selenium’s role in general health is accepted today, at one 
time selenium was a mysterious substance and seen only as a dangerous chemical.  
Selenium: Historical perspective and nutrition  
 
Selenium is an essential nutrient vital to proper cellular metabolism. Once strictly 
considered a toxin, it has been shown to have implications in various aspects of optimal 
cellular and organismal health including  DNA maintenance, protection against oxidative 
stress, and the prevention of cancer.  
 
Selenium’s history as a toxin is more extensive than its tenure as an essential trace 
mineral. The Swedish chemist Jons Jakob Berzelius first identified it as he searched for 
tellurium in paint scrapings5. He named the element after the Greek moon goddess, 
Selene, since he was looking for tellurium, which is named after the Greek Earth goddess 
Tellus. In fact, the medieval adventurer Marco Polo may have been the first historical 
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record of the mineral’s effects on mammalian health. During his expedition through 
China, Marco Polo observed that horses that consumed plants in the mountainous regions 
of the Shaan-Xi Province would experience hoof fractures that would eventually detach 
from the animal. These plants could have stored selenium from the soil since what Marco 
Polo described in his horses is indicative of selenium toxicity. Selenium’s toxicity was 
confirmed in the early 20th century when KW Franke, an American chemist, identified 
the mineral as the culprit in alkali disease, a condition that affected cattle who grazed on 
plants grown in selenium rich soil5.   
 
Although selenium in high amounts can have toxic consequences, a selenium deficiency 
is similarly detrimental and has been associated with two diseases: Keshan disease and 
Kashin-Beck disease. Keshan disease was first characterized in China in 1935 as an 
infectious illness6. Interestingly, the illness has only been diagnosed in populations that 
live in certain regions of China where the soil with particularly low selenium levels7. This 
condition can result in an enlarged heart, cardiac arrhythmias, and congestive heart 
failure. Kashin-Beck disease is similar in that it only occurs in certain regions of China7. 
However, the illness is characterized by osteoarthritis, muscle degeneration7,8. Research 






Selenium is the 34th element on the periodic table and is in the same group as oxygen and 
sulfur. Although selenium shares some attributes with some elements in the same group, 
it is nutritionally unique in terms of its sources. This trace mineral is found in a variety of 
foods including animal organs, animal muscle, and cereals; however, the most 
concentrated levels of selenium are found in that of the Brazil nut. A single Brazil nut 
contains the US adult RDA for selenium – 55 µg.  Yellow tuna also contains a 
considerably higher amount of selenium than other foods – 92 mcg per 3 ounce serving. 
Some of the selenium from these foods can be metabolized into selenoproteins 
 
There are over 24 selenoproteins and many have been shown to be essential as 
antioxidants in different parts of the cell. Dietary selenium compounds, such as 
selenomethionine, selenocysteine, or selenite, are converted to selenoproteins to carry out 
metabolic functions. Before the selenium compounds are incorporated into 
selenoproteins, they must first metabolize to hydrogen selenide (H2Se), which can be 
used to create selenoproteins. H2Se can also be methylated, which has epigenetic 
implications. Selenoproteins are unique because they have their own mRNA codon that 
allows selenium’s insertion into endogenous selenoproteins as selenocysteine co-
translationally. Selenocysteine insertion is designated by the UGA that is otherwise a stop 
codon if the mRNA does not include a stem-loop structure in the 3’-UTR of 
	  4	  
selenoprotein mRNA called the selenocysteine insertion sequence (SECIS) element10. 
This prevents UGA from carrying out its usual role to stop translation and instead to read 
as selenocysteine. The SECIS element allows for the production of all selenoproteins 
including glutathione peroxidase 1-4, thioredoxin reductase, and selenoprotein P. These 
selenoproteins are particularly important in terms of reducing oxidative stress.  
 
The mitochondria produce copious amounts of reactive oxygen species (ROS) within 
cells as a result of the oxidative phosphorylation of adenosine diphosphate (ADP) to 
adenosine triphosphate (ATP) during cellular respiration. These ROS compounds 
typically manifest as H2O2.  The accumulation of ROS results in a toxic cellular 
environment that can have devastating consequences on the organelles and more 
importantly on the genetic material housed within the mitochondria and the nucleus. This 
cytotoxicity can also lead to apoptosis in some instances. However, the cellular 
machinery so diligently developed by the process evolution has a system that codes for 
the production of protective enzymes that can counteract the devastating effects of 
cytotoxicity.  Many of the crucial enzymes involved in this counterattack are 
selenoproteins, GPX1 being the most abundant redox selenoprotein.  
The GPX Family 
 
GPX1 was the first selenoprotein discovered and is found in the cytosol and 
mitochondria. The enzyme was first found in red blood cells where it is involved in 
reducing H2O2 produced as a result of hemoglobin metabolism 11. The active site of 
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GPX1 is the selenocysteine residue and its substrate is H2O2. In this redox reaction, 
H2O2is reduced to water when the selenocysteine of glutathione peroxidase reacts with 
H2O2 to form a 2 water molecules and glutathione disulfide 12. This redox reaction is an 
essential mechanism for reducing H2O2 molecules that can react with superoxide ( O2-) 
and become the hydroxyl radical ( OH) capable of irreversible cell damage. The 
implication of GPX1 in reducing H2O2 in all cells is supported by its implications in 
various diseases, including cancer, diabetes, and cardiovascular disease.  
 
Due to the aspect of cancer being a disease promoted by genomic instability as a result of 
oxidative stress, GPX1 polymorphisms and dysfunction have been associated with 
various cancers. Epidemiological evidence suggests that a low dietary selenium level is 
associated with an increased risk for some cancers13,14 . Levels of GPX1 are strongly 
determined by dietary selenium levels and thus GPX1 has been implicated with various 
cancers. However, it is not conclusive as to the role of GPX1 in some kinds of cancer. A 
classic study showed a protective effect for selenium supplementation in prostate 
cancer15. These findings are controversial when the Selenium and Vitamin E Cancer 
Prevention Trial (SELECT) trial found that there was no significant difference for 
decreased prostate cancer risk with selenium supplementation 16. Interestingly, a 2010 
European study also found an inverse relationship between selenium status and prostate 
cancer 17. In addition, it has been shown that there are decreased levels of GPX1 in 
pancreatic cancer patients when compared to chronic pancreatitis patients, providing 
some evidence for a role of GPX1 in pancreatic cancer 18.  More evidence is needed to 
provide concrete answers as to the role of selenium and GPX1 in prostate cancer. Lung 
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cancer also has implications with selenium deficiency, including GPX1 expression levels. 
A recent Polish study showed that a decreased selenium status resulting in decreased 
GPX1 expression is associated with an increased risk for lung cancer  14.  
 
GPX1 expression may also be involved in metabolic syndromes including type 2-
diabetes, and cardiovascular disease. A Japanese cross-sectional study provided evidence 
for a link between metabolic syndrome and GPX1. It was found that men with a GPX1 
polymorphism were more at risk for metabolic syndrome 19.  Murine models suggest that 
a GPX1 deficiency and increased oxidative stress could result in insulin sensitivity, 
suggesting that decreased GPX1 expression promotes type 2-diabetes  20. The expression 
of GPX1 has also been shown to impact blood pressure. A recent study found that 
hypertension was increased in GPX1 knockout mice 21.  
 
The remaining GPX family members of interest have a similar role as GPX1, but they are 
expressed in other tissues and have slightly different functions. GPX2, also called 
gastrointestinal GPX, is expressed in the epithelial cells of the intestinal tract and reduces 
H2O2 in these cells in a manner similar to that of GPX1 22. GPX2 has also been shown to 
protect against intestinal inflammation and colorectal cancer 23. GPX3 has a catalytic role 
that parallels GPX1, but is secreted from certain cells and performs its H2O2-eliminating 
function in the blood plasma24. GPX3 has been implicated in preventing platelet 
dependent blood clot formation 25 as well as having a regulatory role in normal and 
leukemia stem cell development 26. GPX4 is also called phospholipid hydroperoxide 
glutathione peroxidase due to its role of reducing peroxidized phospholipids 27. This GPX 
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also has an interesting developmental role that has been shown in murine models. Using a 
GPX4 knock out mouse model, it was demonstrated that a lack of GPX4 results in 
disrupted organogenesis resulting in embryonic lethality 28.  
 
The above shows the importance of the GPX selenoproteins in normal cell homeostasis. 
However, there are other selenoproteins that are important to normal cell function, 
including the thioredoxins and selenoprotein P.  
Thioredoxin Reductase Family 
 
The thioredoxin system is essential to the maintenance of proper cell development and 
defense against oxidative stress and was recently reviewed 29. The system includes the 
reducing agents thioredoxin, thioredoxin reductase, and NADPH. The array of enzymes 
in this system help to maintain many cellular redox systems and are therefore associated 
with the pathology of many cellular malfunctions. The thioredoxin reductases are 
selenoproteins and play a critical part in the redox reaction that characterizes the 
thioredoxin system. There are three thioredoxin reductases: TRxR1, TRxR2, and TRxR3. 
These enzymes are similar to the GPX enzymes in that they also carry a SEC residue in 
their catalytically active site.  
 
TRxR1 is involved in the cytosolic reduction of oxidized thioredoxin by NADPH. It is an 
important enzyme due to its effect of reducing ubiquinone to its anti-oxidant form, 
ubiquinone-10, 30 and its involvement in the mitigation of oxidative agents 31. More 
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importantly, thioredoxin reducatase has also been found to have an essential role in 
proper embryogenesis 32 33. Interestingly, TRxR1 is also overexpressed in some forms of 
malignant cancer. One study showed that TRxR1 deficiency reversed the growth of 
tumors in an animal model, suggesting that TRxR1 is essential for the progression of 
tumorigensis 34. TRxR1 has also been implicated in the prevention of neurodegenerative 
disease 35, as well as in the development of breast cancer 36, lung cancer 37, and may have 
a role in chemically induced hepatocarcinogenesis 38.  
 
The other two thioredoxin reductases have functions analogous to TRxR1, but occur in 
different parts of the cell or in different cell types. Mitochondrial thioredoxin reductase is 
the second thioredoxin of interest. In addition to reducing thioredoxin, it also reduces 
selenite, alloxan, and 5,5 ‘-thiobis (2-nitrobenzoic acid) 39. Reminiscent of TRxR1, 
TRxR2 is also upregulated in some carcinomas, indicating that the overexpression of this 
enzyme promotes cancer development 40. However, TRxR2 has also been shown to be 
involved in the protection of cells following an ischemic event 41. Also, TRxR2 has been 
shown to have a more influence in preventing mitochondrial dysfuction in sepsis than 
mitochondrial glutathione peroxidase 42. The third thioredoxin reductase, TRxR3, occurs 
in the testis and has a key role in mammalian spermatogenesis 43.  
 
Another selenoprotein of interest is selenoprotein P. It is a glycoprotein postulated to be 




Selenoprotein P was first identified in the plasma and was the second selenoprotein to be 
identified after GPX1 44. At the time of discovery, its function was unknown, but it 
opened up the possibility of their being more selenoproteins in mammalian systems. 
Selenoprotein P is unique in that it contains 10 selenocysteine residues, whereas the other 
selenoproteins contain only one 45. Its elusive functions have become more apparent in 
the past 10 years. Since it is found in the plasma and responds to higher dosages of 
selenium supplementation, Selenoprotein P acts as a Se nutritional status indicator (along 
with GPX3)46. However, it is better at indicating low selenium status rather than 
excessive selenium status 47. The most important role of selenoprotein P identified is its 
transport of Se from the liver to the tissues to use for selenoprotein production. This 
feature was identified when the gene encoding selenoprotein P was knocked out it mouse 
models. It was found that the concentration of Se in the plasma and other tissues was 
reduced while the concentration of selenium in the liver was increased 48. However, it has 
been shown that the brain’s supply of Se is regulated by a mechanism separate from the 
liver to tissue system described above 49.  
Selenium and Epigenetics 
 
Several micronutrients, including selenium, are implicated in epigenetic modifications. 
Epigenetic changes occur when the cytosine/guanine rich regions of DNA known as CpG 
islands are methylated. Normal methylation is usually regulated and is dispersed evenly 
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on the DNA, which is important for the many cellular functions that occur within the 
diverse mosaic of cells that work in concert to maintain homeostasis. Abnormal 
methylation occurs under at least three conditions: when methylation is not evenly 
dispersed; when DNA is hypomethylated; when DNA is hypermethylated. These 
abnormal methylation patterns may lead to genome instability, which is the hallmark of 
carcinogenesis.  In addition to methylation, DNA acetylation and histone modifications 
are also epigenetic changes that have an impact on genome maintenance. There is a 
growing body of evidence indicating the role of selenium in these epigenetic alterations 
and how they impact carcinogenesis and possibly other metabolic disorders. 
DNA Methylation 
 
The DNA methylation of certain genes can lead to tumor growth promotion. DNA 
methylation usually occurs in cytosine-guanine rich (CpG-rich) regions called CpG-
islands. These epigenetic modifications occur on CpG islands which are usually promoter 
associated50,51. This process can lead to the silencing of genes, an important aspect of 
DNA methylation52. Many studies have shown that some compounds can inhibit the 
methylation of these genes by deactivating DNA methyltransferase (DNMT), an enzyme 
that has the ability to maintain a normal methylation pattern on DNA 53. The three DNA 
methyltransferases are DNMT1, DNMT3A, and DNMT3B.  
 
DNMT1 is the most studied of the DNA methyltransferases due to its high concentration 
relative to the other DNMTs in mammals. One important role of this enzyme is to 
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maintain the methylation pattern during the cell cycle 54. More importantly, some studies 
have shown that DNMT1 is crucial for embryonic development in mouse models 55. 
Another interesting feature of DNMT1 is that it is responsible for the proliferation of 
human cancer cells. In one study, HTC116 cells underwent apoptosis when the DNMT1 
gene was inactivated 56.  
The DNMT3s are also required for proper embryonic development 57. However, there are 
slight differences in the function of each DNMT3. One study employing a mouse model 
found that DNMT3A deficient mice are able to thrive to early adulthood but are smaller 
than usual and the males are rendered infertile, thus allowing for the speculation that 
DNMT3A is important to spermatogenesis 58. Mutations in the gene for DNMT3B result 
in an immunodeficiency disease that can lead to susceptibility of rare diseases 58. 
However, double knockout of DNMT3A and DNMT3B is lethal, as shown by mouse 
models where mouse embryos die during early embryonic development 58.   
 
Selenium and DNMT 
Selenium has demonstrated the ability to inhibit the DNMTs. In one study, selenium 
deficient rats were treated with 5-aza-2'-deoxycytidine, a DNMT inhibitor. It was found 
that these mice exhibited less abnormal crypt formations than the rats fed a diet 
containing normal amounts of selenium. In addition, HT-29 cells cultured in the absence 
of selenium supplementation showed hypermethylated DNA but more DNMT1 
expression, supporting the notion that 5-aza-2'-deoxycytidine may protect selenium 




In addition to DNA methylation, histone modifications represent another mechanism for 
epigenetic changes to occur on the genome. Histones can also be modified by 
methylation, acetylation, phosphorylation, ubiquitination; however, methylation and 
acetylation mainly occur during development and have a long lasting consequences on 
the developing organism60 These changes occur after translation and can lead to changes 
in the chromatin structure, which ultimately has an effect on gene expression 61.  
An acetyl group neutralizes the charge between the DNA and the histone, which leads to 
the unraveling of the complex 62. This unraveling allows for a number of proteins to be 
recruited on to the DNA, thus activating certain genes. Selenium has been implicated in 
the acetylation of histones and has been found to affect prostate cancer cells. Increased 
acetylation of some histones are postulated to be an indicator for genome instability and 
thus the onset of tumorigenesis. Selenium treatment decreased deacetylation of histone 
H3, which suggests a possible mechanism for selenium in cancer prevention 63.  
Stress-induced senescence  
 
The cells of most organisms do not replicate indefinitely. Although there are some cells 
that can replicate for an innumerate amount of times, such as cancer cells, and some 
organisms that are essentially immortal, like Tetrahymena thermophile 64 most cells do 
not have the capability to forgo cell death after a certain amount of replications. Most 
cells go through a torrent of damage as they replicate, which are repaired through various 
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mechanisms as the entire genome replicates. However, as the telomeres on the ends of 
chromosomes shorten with each replication, there comes a time in the life cycle of a cell 
when it stops dividing. This permanent arrest of the cell cycle is called senescence.  
Senescence is the result of a complicated cascade of cellular events65. It can be induced 
via two distinct pathways: after a specific number or replications or from environmental 
stimuli that affect the DNA and lead to the formation of reactive oxygen species. These 
two pathways are respectively known as replicative and stress induced senescence.  
 
The role of replicative senescence is a part of the life cycle of most cell types. In 1961, 
Leonard Hayflick first observed this phenomenon in human embryonic tissue66. Before 
his discovery, it was believed that cells were essentially able to replicate indefinitely67. 
Hayflick observed that cells from embryonic tissues were only capable of dividing a 
certain number of times after they were sub-cultured66. The cells would eventually start 
dividing slower and ultimately die. Further studies showed that specific markers were 
able to indicate whether a cell had undergone replicative senescence. The shape of the 
cell is one such indicator. Cells undergoing replicative senescence may appear stretched 
and flattened when compared to their non-senescent counterpart68. Another marker is the 
increased activity of the enzyme senescence-associated β-Galactosidase.  Ultimately, 
these markers are the result of the shortening of telomeres that occur with each cell 
replication. With each round of cell replication, the telomeres, the guanine-rich ends of 
chromosomal DNA, shorten. This is mainly due to the absence of telomerase activity, the 
enzyme that maintains the integrity of telomeres, in most cells. Telomerase is highly 
expressed in immortal cells, such as those of many cancer cells69. 
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That stress induced senescence is more intricate than replicative senescence is how it 
induced. Stress induced senescence occurs when DNA is damaged and cells experience 
certain forms of stress. It can be induced by a variety of stressors, including reactive 
oxygen species, various trace minerals when in excess, and radiation. These stressors can 
lead to DNA double strand breaks, which are sensed by the MRN complex and in turn 
causes the ATM protein pathway to be activated 70. The ATM pathway initiates a cascade 
of downstream protein activation, prompting for the mediation of the DNA damage 
response. The downstream proteins affected by ATM include the proteins p53 and Chk2, 
which are phosphorylated by the ATM protein. The Chk2 protein ultimately leads to the 
p53 protein, which is a tumor suppressor. The p53 protein can then activate the p21 
protein pathway that will eventually activate the Rb protein, leading to cellular 
senescence 71. This has been established based on evidence from knocking out the genes 
for ATM and p53 in mice, which inactivates the senescent response.   
Stress induced senescence is often the saving grace that leads to the non-proliferation of 
cancer cells. An overexpression of the RAS oncogene causes normal cells to go into a 
senescent state 72. The RAS oncogene is required for the MAPK cascade, which 
upregulates the proteins p16INK4a and p19ARF, the mediators for the RAS oncogenic 
senescence.  
 
Other features of senescence include senescence associated heterochromatin foci 
(SAHF). SAHF are structures that appear when cells are in a senescent state. Although 
they appear in senescent cells, they only appear in stress-induced senescence. The 
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structure is characterized by a large nucleus and points of DNA, and can be visualized 
under a fluorescence microscope after being stained with 4',6-diamidino-2-phenylindole 
(DAPI). Each point of DNA when stained with DAPI is believed to be a single 
chromosome 73. This single chromosome has intertwined within it proliferation-
promoting genes that consequently lead to the senescent state.  
 
There are a couple of markers of that can be employed to show the SAHF state more 
completely. These include histone variants and heterochromatin proteins, as well as 
certain chromatin regulators.  
 
Histones are proteins that condense DNA into the compact form when it is structured as 
chromosomes. These proteins are very rich in the positively charged amino acids lysine 
and arginine. Histone H3 is of particular interest because its amino acid sequence is 
nearly the same in all eukaryotic cells 74, suggesting that histone H3 is an important 
protein conserved during evolution Histone H3 is also a protein that is involved in the 
formation of SAHF. When the chromosomes that are the foci condense, which are visible 
by use of DAPI staining, the position 9 Lysine of histone H3 can be tri-methylated 75. 
This tri-methylated state of histone H3 allows for the recruitment of proteins, specifically 
HP1-γ 76, to heterochromatin  
 
Heterochromatin proteins are involved in a variety of epigenetic activities, including gene 
transcription and chromatin structural organization 77. There are three isoforms of this 
protein found within mammalian cells: HP1-α, HP1-β, and HP1-γ. The structure of these 
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proteins consists of an amino-terminal chromodomain, a hinge region, and a carboxyl-
terminal chromo-shadow domain 77. They have the ability to associate with chromatin by 
being recruited to sites where a di-methylated or tri-methylated histone H3 occurs, where 
they have the function of repressing or activating genes 77.  All three are a part of a DNA 
damage response that can be induced by ultraviolet induced lesions and DNA double 
strand breaks. The three proteins are recruited to sites of UV induced lesions where they 
play a critical role in the repair of these lesions. It has been observed that these proteins 
are essential in their role in mediating UV induced damage to DNA 75. The protein HP1-γ 
is especially important in the formation of SAHF. HP1-γ becomes phosphorylated at the 
position 93 serine residue in senescent cells. This allows HP1 to become deposited into 
SAHF and might have the propensity to maintain the structure of these foci. 
 
The chromatin regulators involved in the formation of SAHF are HIRA and ASF1a. 
HIRA and ASF1a are proteins involved in depositing variants of histone H3 into 
nucleosomes 78. These two proteins mediate the formation of the histone variant µH2A, 
which is another marker for SAHF 78. 
 
The process of SAHF forming begins with the senescence-inducing event. The formation 
of SAHF forms is a process that involves various steps eventually leading to permanent 
cell cycle exit. Many of the steps that lead to the formation of these structures is poorly 
defined, but there exists a general chain of events that typically take place as SAHF form. 
The first event that takes place is the condensation of the chromosomes in the cell. These 
are visible by using immunofluorescence when stained with DAPI. The proteins involved 
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in this event include HIRA and ASF1a 76. As described above, these proteins mediate the 
formation of µH2A. One of the events that follow is the tri-methylation of the position 9 
lysine on Histone H3 (H3K9Me3). Once histone H3 is methylated, HP1 proteins, 
specifically HP1γ, can bind to it. These proteins, along with the condensed chromosomes, 
help to elucidate the SAHF structure.  
The above described a better-known scenario for SAHF formation. The functions and 
formation of SAHF are still being discovered.  Some theorize that SAHF actually 
contribute to the aging process, as some of the structures involved in their formation are 
observed in the aging cells of animals. One example is the presence of the HIRA protein 
in the dermal fibroblasts of aging baboons 77.  
 
Senescence is the penultimate fate of a cell. They are unable to undergo the process of 
mitosis and remain stagnant. After the state of senescence, a cell will die. Senescence is 
seen as a way to abrogate the proliferation of pre-cancer cells, which is an established 
early tumorigenesis barrier79,80 In the Cheng Lab, we have previously shown that 
selenium compounds at sub-lethal doses can activate a senescence response in non-
cancerous but not in cancerous cells, consistent with the view that senescence is an early 
tumorigenesis barrier and providing a new avenue towards the mechanistic understanding 
of selenium chemoprevention at the early stage of tumorigenesis81. 
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We used MRC-5 cells to explore the possibility that selenium-induced senescence 
involves SAHF. These cells were originally obtained from Coriell Institute (Camden, 
NJ). Cells were grown in Eagle’s minimum essential medium (Mediatech Inc., Herndon, 
VA) that included a mixture of 15% fetal bovine serum, essential amino acids, non-
essential amino acids, vitamins, and a penicillin/streptomycin solution. They were 




After cells were grown to confluency, they were trypsinized and seeded onto a 6-well 
dish. To determine the senescent response, the cells were incubated with 2 uM 
methylseleninic acid (MSeA). The anhydrous MSeA obtained from Sigma-Aldrich was 
dissolved in phosphate-buffered saline. To determine if the selenium-induced senescent 
response involves ATM and DNA-PK, cells were incubated with KU55933, a DNA-PK 
inhibitor, and NU7026, an ATM inhibitor, both obtained from Tocris and dissolved in 
dimethyl sulfoxide (DMSO). Cells treated with MSeA only were incubated for 48 hours 
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followed by a single wash of PBS, while the cells pretreated with KU55933 or NU7026 
were incubated for 24 hours, washed once with PBS, followed by a 48 hour MSeA 
treatment and subsequently washed once again with PBS. Immunofluorescence 
experiment was performed immediately following the indicated recovery time. 
Coverslips were washed 3 times with PBS, fixed in 4% paraformaldehyde in PBS for 10 
minutes, washed again 3 times with PBS, permeabilized in 90% methanol for 10 minutes 
in -20°C, and then washed three times with PBS once more. The coverslips were then 
incubated in 0.3% Triton-X for 10 minutes, washed 3 times with PBS, and then blocked  
in 3% BSA for 1 hour, followed by a wash with PBS 3 times. Coverslips were 
subsequently incubated overnight in -4°C with antibodies against heterochromatin marker 
proteins H3K9me3 (Abcam, ab8898, 1:1000). Coverslips were washed 5 times with PBS-
T (1% Tween-20 in TBS), incubated at room temperature in secondary antibodies 
(Alexafluor 594 anti-rabbit at 1:500) for 1 hour. After washing the coverslips 5 times 
with PBS-T, the cells were mounted on slides using a drop of ProLong® Gold antifade 
reagent containing DAPI (Invitrogen). We used a Zeiss AxioObserver 100 fluorescence 
microscope to obtain images. Fifteen pictures were taken randomly from each slide. We 








Quantification of SAHF positive cells 
 
I used a positive/negative approach that was used previously in the Cheng Lab to 
determine whether a cell was positive for SAHF and to determine colocalization 81,82. 
Using the 15 randomly taken pictures, I counted the SAHF positive cells and used this 
number to calculate the percentage of SAHF positive cells on each slide.  
The ascertainment of colocalization was determined using the intensity of the DsRed (the 
secondary antibody against H3K9me3) and DAPI. I counted the cells that showed 
colocalization as positive and used this number to calculate the percentage of 




Statistical analysis was completed using Microsoft® Excel for Mac 2011 Version 14.3.2. 
To ascertain the statistical significance between the treatments and the control, we used a 
two-tailed Student’s t test (p<0.05). 
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Chapter 3: MSeA induces SAHF in a manner depending on the kinase 
activity of ATM and DNA-PK 
MSeA induces SAHF 
Prior research in our lab suggested that treatment of non-cancerous MRC-5 cells with 
MSeA resulted in SAHF (Fig 1) 83. This piece of evidence gave an indication that the 
epigenome may be involved in the regulation of selenium-induced senescence. To test the 
possibility that selenium-induced senescence involves SAHF formation, we treated 
MRC-5 normal lung cell fibroblasts with 2µM MSeA for 48 hours followed by a 7-day 
recovery period. We interpreted data from the third day of recovery. Using 
immunofluorescence, we observed that distinct punctate foci developed when using 
DAPI (Fig 2a). Upon further observations using a SAHF marker, H3K9me3, we observed 
that this marker also revealed single spotted structures indicative of SAHF (Fig 2a). 
Quantification of the SAHF showed a significantly greater amount of SAHF development 
when compared to the control (Fig 2c). These results suggest that MSeA treatment does 
induce SAHF. In addition, we observed an overlapping colocaliation pattern when 
viewing the merged image of the fluorescence-enriched regions of DAPI-stained DNA 
and H3K9me3 (Fig 2a). This is also reflected in the quantification, where we found that a 
significantly greater amount of colocalization occurred in cells treated with MSeA when 
compared to the control (Fig 4). These results intimate that selenium-induced senescence 
involved SAHF.  
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Selenium-induced senescence involves ATM and DNA-PK 
 
DNA-damage induced senescence has been shown to involve the ATM kinase79,80. The 
Cheng lab has established that ATM and DNA-PK are involved in selenium-induced 
senescence81. It was from these that we hypothesized that SAHF, when induced by 
selenium, involves the ATM and DNA-PK.  
 
To test the possibility that selenium-induced SAHF involves DNA-PK and ATM, we 
pretreated MRC-5 normal lung cell fibroblasts with KU55933, an ATM kinase inhibitor, 
and NU7026, a DNA-PK kinase inhibitor. This pretreatment was followed by a 2 µM 
MSeA treatment for 48 hours followed by a 7-day recovery period. As in the first 
experiment, we interpreted the data from the third day of recovery.  
 
When we observed the cells pretreated with KU55933, we noticed that localization 
patters of DAPI and H3K9me3 was similar to that appeared when the cells were treated 
only with MSeA (Figure 3).  However, the MSeA-induced co-localization between 
SAHF and H3K9me3 was significantly hampered when the cells were pre-treated with 
KU55933, suggesting that selenium-induced SAHF formation involves the kinase activity 
of ATM. 
 
The observations obtained from the cells pretreated with NU7026 yielded results distinct 
from the cells pretreated with KU55933. Interestingly, pretreatment with NU7026 did not 
produce large SAHF structures as seen with the KU55933 pretreated cells. Instead, a 
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more dispersed pattern of smaller focus formations developed that is reminiscent of DNA 
damage foci (Figure 2). Interestingly, H3K9me3 also appeared as small foci, although the 
degree of co-localization with the condensed DNA region was reduced compared to that 
treated with MSeA only (Figure 4).  Since NU7026 pre-treatment results in a MSeA-
induced DNA pattern atypical of SAHF, it is difficult to determine the significance of 
DNA-PK in selenium-induced SAHF formation. Nonetheless, despite the many 
overlapping roles of ATM and DNA-PK in the cellular response to DNA damage, ATM 



















Fig 2. Immunofluorescent analyses of SAHF formation in response to MSeA treatment, 
KU55933 and MSeA treatment, or NU7026 and MSeA treatment. Cells were (A) treated 
with  MSeA (2μM, 48h), (B) pretreated with KU55933 (10μM, 24h) and then a 
treatment of MSeA (2μM, 48h), and (C) pretreated with NU7026 (10μM, 24h) and then 
a treatment of MSeA (2μM, 48h) was added. All the cells were then grown in a 





Fig. 3. Quantification of SAHF formation in response to MSeA treatment, KU55933 and 
MSeA treatment, or NU7026 and MSeA treatment. SAHF positive cells with numerous, 
small foci was determined by counting the SAHF as indicated by DAPI and H3K9me3 




Fig. 4: Quantification of SAHF formation in response to MSeA treatment, KU55933 and 
MSeA treatment, or NU7026  and MSeA treatment. SAHF positive cells with numerous, 
small foci was determined by measuring the co-localization pattern of DAPI and 


























Chapter 4: Discussion and Conclusion 
Discussion 
 
A cascade of changes occurs when a cell undergoes the process of senescence. SAHF are 
involved with the maintenance of the senescent state, as well as having involvement with 
interrupting the recruitment of proliferating promoting genes84. Previous research 
demonstrates that non-cancerous cells treated with selenium compounds at low doses 
display senescence 8262. These data led us to speculate a role of SAHF in selenium-
induced senescence.  
 
As indicated by the markers that detect SAHF, our results show that these structures do, 
in fact, after MSeA treatment in MRC-5 fibroblasts. The use of DAPI staining reveals 
large and distinct formations of DNA enrichment in cells treated with MSeA with or 
without ATM kinase activity. These structures were more dispersed and widespread in 
cells pretreated with the DNA-PK kinase inhibitor, NU 7026.   One of the markers used 
to detect SAHF is H3K9me3. The role of H3K9me3 is to repress certain genes in 
mammalian genomes 85 . Our results show that robust H3K9me3 foci are formed when 
cells were treated with MSeA with or without DNA-PK kinase inhibition. These data 
suggest that MSeA treatment has an effect on the methylation of histone H3 independent 
of DNA-PK kinase activity. However, these robust foci were not seen when cells were 
pretreated with the ATM inhibitor. As these foci are more reminiscent of DNA damage 
foci, it is possible that lack of DNA-PK pathway potentiate cells to MSeA-induced DNA 
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damage. Instead of the less toxic senescence is induced, the same dose of MSeA induces 
severe DNA damage in the MRC-5 cells with defective DNA-PK kinase activity. Future 
studies are needed to elucidate the role of DNA-PK and ATM in the DNA damage 
response during the development of selenium-induced SAHF formation and senescnece.   
 
The colocalization of H3K9me3 with SAHF strongly implicate a senescence state 86 . 
Cells that were treated with MSeA only and with the DNA-PK inhibitor only showed a 
robust colocalization pattern (Fig. 1A, 1B). These pieces of evidence further suggest that 
selenium-induced senescence involves SAHF. Interestingly, pretreatment with the ATM 
inhibitor also showed a considerable amount of colocalization between the two markers. 
This suggests that the structures that form when cells are pretreated with the ATM 
inhibitor also generate SAHF, however, the process may involve other interactions that 
have yet to be determined.  
 
There are strengths and limitations about this study that are worth mentioning. A strength 
of this research is that I used reagents that are useful at determining whether or not a 
structure is SAHF. By using these markers such as DAPI and H3K9me3, I was able to 
provide evidence for the presence of SAHF. This straightforward approach provides a 
simple yet complete way to collect data and make conclusions. However, there are some 
limitations with my experiment. One limitation is that I could have used another marker, 
heterochromatin protein 1 gamma (HP1γ). This marker would have yielded more 
evidence for the structures being SAHF. However, even without this marker, H3K9me3 
and DAPI are credible indicators for heterochromatin formation. Another limitation to 
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my study is that I am unable to understand any mechanistic features of SAHF formation 
as a result of selenium-induced senescence. Although I observed the structures in my 
experiments, I am still unclear on what are the mechanisms involved in their creation. 
More studies are needed to elucidate the pathways that lead to SAHF formation during 
selenium-induced senescence.  
Conclusion 
The study of senescence could further the knowledge base of cancer research, thus 
generating an understanding of this prolific illness and ways to prevent or treat it. From 
my studies involving selenium, the DNA damage response, and the mechanisms leading 
to selenium-induced senescence, we can understand how this trace mineral could be a 
tool to counteract tumorigenesis. Through the study described above, we are closer to 
understanding the structures involved in creating the senescent state during selenium-
induced senescence. This piece of evidence could lead to a better understanding how the 
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